BK With VST for Kidney Transplant Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

May 14, 2024

Study Completion Date

May 14, 2024

Conditions
Kidney Transplant InfectionBK Virus Infection
Interventions
DRUG

BK-specific T cells from Donor Lymphocytes

"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis, enriched for BK-specific CD4+ and CD8+ T cells~Suspension of BK-specific T cells in approximately 7 mL (5-10 mL range for volume of IMP) of 0.9% NaCl with 2.5% HSA at a cell dose of: ≥ 300 and ≤ 5,000 BK virus-specific CD3+ T cells/kg body weight (BW).~IV bolus injection; IV push of IMP over approximately 2-4 minutes, resulting in an infusion rate of approximately 3 mL/min."

Trial Locations (1)

53705

University of Wisconsin School of Medicine and Public Health, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT05042076 - BK With VST for Kidney Transplant Patients | Biotech Hunter | Biotech Hunter